Intercept Pharmaceuticals Inc $ 96.65 0 (0%)
Volume:
574,038
Avg Vol (1m):
797,192
Market Cap $:
3.16 Bil
Enterprise Value $:
2.98 Bil
P/E (TTM):
0.00
P/B:
24.20
Financial Strength | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.34 | ||
| Equity-to-Asset | 0.16 | ||
| Debt-to-Equity | 4.07 | ||
| Debt-to-EBITDA | -1.82 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | -0.7 | ||
| Beneish M-Score | -2.74 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -130.51 | ||
| Net Margin % | -143.09 | ||
| ROE % | -457.16 | ||
| ROA % | -52.94 | ||
| ROC (Joel Greenblatt) % | -2382.85 | ||
| 3-Year Revenue Growth Rate | 278 | ||
| 3-Year EBITDA Growth Rate | -0.5 | ||
| 3-Year EPS without NRI Growth Rate | -4.3 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 24.2 | ||
| PS Ratio | 12.78 | ||
| EV-to-EBIT | -10.03 | ||
| EV-to-EBITDA | -10.23 | ||
| EV-to-Revenue | 12.76 | ||
| Current Ratio | 5.49 | ||
| Quick Ratio | 5.49 | ||
| Days Sales Outstanding | 51.24 | ||
| Days Payable | 2590.9 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 24.2 | ||
| Price-to-Median-PS-Value | 0.1 | ||
| Earnings Yield (Greenblatt) % | -9.97 |